Transcatheter treatment options for aortic regurgitation (AR) bring a new, less invasive approach to the table, Stephan von Bardeleben (University Medical Center, Mainz, Germany) tells Cardiovascular News at PCR London Valves 2022 (27–29 November, London, UK), potentially opening up transcatheter aortic valve implantation (TAVI) to a currently underserved population.
Among the first TAVI devices to present a tailored option for AR patients is Trilogy (JenaValve)—a recently CE mark-approved transfemoral TAVI system for both AR and aortic stenosis—whose “intelligent” design has yielded encouraging results to date, according to Von Bardeleben.
In this interview, Von Bardeleben sets out some of the unique design that make the device a suitable option for AR, details some of the existing clinical data underpinning the early optimism surrounding Trilogy, and also touches upon some of the important questions that are still to be answered in relation to TAVI in AR.
This video is sponsored by JenaValve.
